MTNB News and Press, Matinas Biopharma Holdings Inc. From 12/21/23

Written Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design Partnership Discussions Remain Ongoing for MAT2203 BEDMINS...

2023-11-08 22:44:10 ET Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Conference Call November 08, 2023 04:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO ...

FDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to strengthen commercial opportunity without increasing study size Pat...

2023-11-07 09:26:29 ET Let’s talk penny stocks , those under-five-dollar shares that buzz with potential. They’re nimble, sensitive to the slightest news, and can pivot on a dime. Here, we’ll explore the day’s hot penny stocks , all freshly churned by...

2023-11-07 08:01:01 ET More on Matinas Biopharma Matinas BioPharma Holdings, Inc. (MTNB) Q2 2023 Earnings Call Transcript Matinas BioPharma stock soars 80% on antifungal drug update Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earnings ...

BEDMINSTER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform technology, announces positive results from an in ...

BEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, an...

2023-10-12 11:26:53 ET Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer’s acquisition of Seagen, Eli Lilly’s buyout of...

2023-10-11 12:45:29 ET Gainers: Matinas Biopharma Holdings ( MTNB ) +123% . Phio Pharmaceuticals Corp ( PHIO ) +58% . Athena Consumer Acquisition Corp ( ACAQ ) +55% . Tupperware Brands Corporation ( TUP ) +38% . Avalo Therapeutics ( AV...

2023-10-11 12:13:39 ET DENVER, Colo., Oct. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Tempest Therapeutics (NASDAQ: TPST), Phio Pharma (NASDAQ: PHIO), Athena Consumer Acq (AMEX: ACAQ), Matinas Bi...